CNTB

Connect Biopharma Holdings Limited

$0.68

-9.08%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-39.5%
3M-63.9%
YTD-68.3%
1Y-52.8%
52-week range—
Beta0.57
Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth51
Risk47
Performance57
Valuation26
Profitability17
Leverage44
Sentiment66
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$64K-99.8%
Net income-$55.5M
Net margin—
Historical fundamentals

Revenue exposure

Regions, segments, customers and suppliers

Valuation

CNTBIndustryP/E—89.69P/S14.5511.88EV/EBITDA—67.10P/B1.606.22PEG—4.02
Dividend yield0.00%
Every valuation metric